Perreault Melissa L, Hasbi Ahmed, O'Dowd Brian F, George Susan R
1] Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada [2] Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada.
Neuropsychopharmacology. 2014 Jan;39(1):156-68. doi: 10.1038/npp.2013.148. Epub 2013 Jun 18.
The pharmacological modification of dopamine transmission has long been employed as a therapeutic tool in the treatment of many mental health disorders. However, as many of the pharmacotherapies today are not without significant side effects, or they alleviate only a particular subset of symptoms, the identification of novel therapeutic targets is imperative. In light of these challenges, the recognition that dopamine receptors can form heteromers has significantly expanded the range of physiologically relevant signaling complexes as well as potential drug targets. Furthermore, as the physiology and disease relevance of these receptor heteromers is further understood, their ability to exhibit pharmacological and functional properties distinct from their constituent receptors, or modulate the function of endogenous homomeric receptor complexes, may allow for the development of alternate therapeutic strategies and provide new avenues for drug design. In this review, we describe the emerging neurobiology of the known dopamine receptor heteromers, their physiological relevance in brain, and discuss the potential role of these receptor complexes in neuropsychiatric disease. We highlight their value as targets for future drug development and discuss innovative research strategies designed to selectively target these dopamine receptor heteromers in the search for novel and clinically efficacious pharmacotherapies.
长期以来,多巴胺传递的药理学修饰一直被用作治疗多种精神健康障碍的治疗手段。然而,由于如今许多药物疗法并非没有显著副作用,或者它们只能缓解特定的一组症状,因此识别新的治疗靶点势在必行。鉴于这些挑战,多巴胺受体可形成异聚体这一认识显著扩展了生理相关信号复合物以及潜在药物靶点的范围。此外,随着对这些受体异聚体的生理学和疾病相关性的进一步了解,它们展现出与组成受体不同的药理学和功能特性,或调节内源性同聚体受体复合物功能的能力,可能会促进替代治疗策略的开发,并为药物设计提供新途径。在本综述中,我们描述了已知多巴胺受体异聚体新出现的神经生物学、它们在大脑中的生理相关性,并讨论了这些受体复合物在神经精神疾病中的潜在作用。我们强调它们作为未来药物开发靶点的价值,并讨论旨在选择性靶向这些多巴胺受体异聚体以寻找新型且临床有效的药物疗法的创新研究策略。